Customized nanomedicines can be used in a variety of ways, including angiogenesis suppression, vascular disruption, and vascular infarction. In the angiogenesis suppression approach, VEGF, VEGFR, mTOR, EGFR, bFGF, ROS, and other components have become promising therapeutic targets. The nanomedicine system has successfully inhibited tumor neovascularization using gene silencing, chemotherapy, photothermal therapy, and other therapies. In the vascular disruption approach, VDAs supplied by nanomaterials were bonded with the bonding sites of CA4, COL, PTX, and other medications on microtubules to promote rapid disintegration of tumor vascular wall cells. Combining many medicines increased the tumor treatment outcome even more. For example, disruption of tumor blood arteries caused by nanoparticle-mediated physical methods combined with chemotherapy resulted in effective treatment in a large volume tumor model. The vascular infarction methodology uses a variety of carriers, including nanoparticles, DNA nanorobots, platelet membranes, and others, to carry thrombin, tTF, and other drugs to generate local thrombosis and provide safe and effective tumor treatment.
Embryonic vascular disruption adverse outcomes: Linking high throughput signaling signatures with functional consequences
